biomarker discovery and assay developmentlifescienceevents.com/wp-content/uploads/... · day 2:...
TRANSCRIPT
This year there are three main topics for discussion
Screening and Prevention Research
Biomarker Discovery and Assay Development
Anti-Cancer Therapeutics
With plenty of opportunity for networking and debate, this informal international meeting will bring you up to date with current research and thinking regarding cancer screening, prevention and treatment.
www.controllingcancersummit2014.com
Principal Sponsors
Gold Sponsor
Bronze Sponsors
Media Partner
Table of Contents Program Outline ........................................................................................................................................................ 6
Day 1: Advances in Cancer Screening and Prevention Research........................................................................... 6
Session Chair: Dr Eleanor O'Sullivan, Clinical Lecturer, Cork University Dental School & Hospital, Ireland ..... 6
Day 2: Cancer Biomarker Discovery and Assay Development .............................................................................. 6
Session Chair: Mukesh Verma, Chief, Methods and Technologies Branch, Epidemiology and Genetics
Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National
Institutes of Health. Rockville, MD, USA............................................................................................................ 6
Mukesh Verma ................................................................................................................................................... 6
Day 3: Anti-Cancer Therapeutics: From research to trials to treatment ............................................................. 6
Session Chair: Dr Ann White, Senior Research Fellow, University of Southampton, UK .................................. 6
Agenda ....................................................................................................................................................................... 7
Day 1: Advances in Cancer Screening and Prevention Research ............................................................................ 7
Introduction by the Chair........................................................................................................................................ 7
Estonian experience in establishing a cancer screening registry: opportunities and challenges of the e-health era ......... 7
Head and Neck Cancer (HNC) Screening in National and High-risk Populations in Ireland........................................... 7
Quality Control in Cervical Cancer Screening .......................................................................................................... 7
Oral Presentations ............................................................................................................................................... 7
Oral Presentations ............................................................................................................................................... 7
Oral Presentation ................................................................................................................................................. 7
COMPARISON OF UPTAKE OF COLORECTAL CANCER SCREENING BASED ON FAECAL IMMUNOCHEMICAL
TESTING (FIT) IN MALES AND FEMALES: A SYSTEMATIC REVIEW AND META-ANALYSIS .................................. 7
Towards implementation of lung cancer screening: refining methods to maximise effectiveness ................................... 7
The European Prostate cancer screening trial ERSPC: outcomes and methods for risk stratification. .......................... 7
Mammography Screening for Breast Cancer. Is it living up to its promise? ................................................................ 7
A New Era in the Control of Breast Cancer .............................................................................................................. 7
Day 2: Cancer Biomarker Discovery and Assay Development ................................................................................ 8
Introduction by the Chair........................................................................................................................................ 8
Mesenchymal and rare colorectal carcinomas as a paradigm to identify new biomarkers/alterations of tumor
aggressiveness. New pathways, and an unexpected role of chromatin remodeling complexes .................................... 8
RNAscope® - providing a unique insight into the interplay between cancer cells and the tumor microenvironment ......... 8
Epigenetic markers of progression and treatment response in breast cancer .............................................................. 8
Oral Presentation ................................................................................................................................................. 8
UNDERSTANDING FANCONI ANEMIA-ASSOCIATED INFLAMMATION THROUGH THE HIV AUXILIARY PROTEIN
VPR ..................................................................................................................................................................... 8
Nucleosomics® - A novel epigenetic biomarker discovery platform ............................................................................ 8
Association of p53 and eIF4E with local recurrence in head and neck squamous cell carcinoma: Should we change the
way used to assess the tumour margins? ................................................................................................................ 8
Epigenetic biomarkers in cancer risk assessment, screening, and prevention ............................................................. 8
Mass spectrometry based discovery and quantitation of liver disease biomarkers before progression to cancer ............. 8
Paediatric lymphoma: diagnosis, biomonitoring and therapy ..................................................................................... 8
Day 3: Anti-Cancer Therapeutics: From research to trials to treatment .................................................................. 9
Introduction by the Chair........................................................................................................................................ 9
The selective targeting of cell survival pathways in cancer cells ................................................................................ 9
Early Oncology Drug Development - Current Strategies and Future Challenges.......................................................... 9
Translating antibodies engineered with IgE Fc regions to elicit enhanced effector functions for cancer therapy .............. 9
Oral Presentations ............................................................................................................................................... 9
Oral Presentations ............................................................................................................................................... 9
Reporter Bioassay: A Novel, Bioluminescent Cell-Based Assay for Quantifying Fc Effector Function of Therapeutic
Antibodies ............................................................................................................................................................ 9
Dr Craig Malcolm, Product Manager, Promega UK Ltd, Delta House, Southampton Science Park, Southampton, UK .... 9
Oral Presentation ................................................................................................................................................. 9
Patient Delay in accessing Breast Cancer Care in a LIC ..................................................................................... 9
FKBPL and peptide derivatives and their dual anti-angiogenic and anti-cancer stem cell activity .................................. 9
Targeting leukemic stem cells to improve treatment of chronic myeloid leukemia. ....................................................... 9
About the Speakers ................................................................................................................................................. 10
Day 1 .................................................................................................................................................................... 10
Piret Veerus ..................................................................................................................................................... 10
Alenka Repše Fokter ........................................................................................................................................ 10
David Baldwin .................................................................................................................................................. 10
Monique J. Roobol ........................................................................................................................................... 10
Anthony Miller, ................................................................................................................................................ 10
László Tabár ..................................................................................................................................................... 10
Day 2 .................................................................................................................................................................... 11
Massimo Pancione: .......................................................................................................................................... 11
Thomas Fleischer ............................................................................................................................................. 11
Bevin Gangadharan, ........................................................................................................................................ 11
Rama Jayaraj, ................................................................................................................................................... 11
Abhinav Kumar, ............................................................................................................................................... 12
Suzanne Turner ................................................................................................................................................ 12
Day 3 .................................................................................................................................................................... 12
Mark Guthridge ............................................................................................................................................... 12
Hendrik-Tobias Arkenau .................................................................................................................................. 12
Sophia N. Karagiannis ...................................................................................................................................... 12
Xiaoyan Jiang ................................................................................................................................................... 13
Discussion Sessions .................................................................................................................................................. 13
Session breaks ......................................................................................................................................................... 13
Lunch ....................................................................................................................................................................... 13
All the chicken in our lunch buffet is Halal ...................................................................................................... 13
We have a number of dishes that are gluten free ........................................................................................... 13
We have a range of vegetarian dishes which are separated from the meat and fish dishes ......................... 13
Frequently asked questions about our events ........................................................................................................ 14
Is the delegate list available?............................................................................................................................... 14
Can I have the speakers slides? ........................................................................................................................... 14
Can I have a notepad? ......................................................................................................................................... 14
How can I keep up to date with Euroscicon Events? ........................................................................................... 14
I don’t want my photograph on any Euroscicon promotional material .............................................................. 14
Is there WIFI? ....................................................................................................................................................... 14
Can I have a CPD certificate? ............................................................................................................................... 14
Program Outline
Day 1: Advances in Cancer Screening and Prevention Research
This session will discuss current research and clinical trials for the prevention of cancer, focusing on screening, early detection and chemoprevention. Session Chair: Dr Eleanor O'Sullivan, Clinical Lecturer, Cork University Dental School & Hospital, Ireland As Clinical Lecturer in Oral/Maxillofacial Surgery and Member of Regional HNC MDT, Eleanor O'Sullivan is involved in clinical care of HNC patients from diagnosis to palliation. Research interests include primary prevention, early detection and optimizing HNC patient’s journey. As a member of ICS HNC Expert Advisory Panel and Chair of MHNCAI, she played a lead role in developing and implementing National Mouth Cancer Awareness Days (MCAD) 2010-2013. MHNCAI has established links with HNC awareness groups in UK, Scotland, USA and Sudan. She has conducted several HNC screening studies and collaborates with National Cancer Registry, Dublin City University and Khartoum University, Sudan.
Day 2: Cancer Biomarker Discovery and Assay Development
Whilst numerous challenges exist in translating biomarker research into the clinical space; a number of gene and protein based biomarkers are already being used at some point in patient care. This session will discuss the further discovery and assay development of genetic, epigenetic, proteomic, glycomic, and imaging biomarkers which can be used for cancer diagnosis, prognosis, and epidemiology. We provide an informal atmosphere for discussion and debate.
Session Chair: Mukesh Verma, Chief, Methods and Technologies Branch, Epidemiology and Genetics
Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National
Institutes of Health. Rockville, MD, USA
Mukesh Verma is a Program Director and Branch Chief in the Methods and Technologies Branch (MTB),
Epidemiology and Genomics Research Program (EGRP) of the National Cancer Institute (NCI), National Institutes
of Health (NIH). He provides direction in the areas of biomarkers, early detection, risk assessment, epidemiology
and prevention of cancer. Dr. Mukesh Verma holds a M.Sc. from Pantnagar University and a Ph.D. from Banaras
Hindu University. He has published 137 research articles, book chapters reviews and edited three books in
cancer biomarker, epigenetics and epidemiology field. He represents NCI in the NIH Epigenome Roadmap.
Day 3: Anti-Cancer Therapeutics: From research to trials to
treatment This session will discuss development of therapies for cancer treatment including, but not exclusively biologicals, looking at discoveries in the laboratory to clinical phase trials. This is not only an ideal place to showcase research and development but also to discover what may become new on the market and to network with experts in the field. In addition, this session will highlight ground-breaking developments in cancer therapeutics providing a unique opportunity to listen and contribute to discussions on a variety of topics including small molecule and antibody based drugs, genetic studies, gene therapy and clinical trials
Session Chair: Dr Ann White, Senior Research Fellow, University of Southampton, UK Ann White is a Senior Research Fellow within the Cancer Sciences Unit, University of Southampton. Her research is focused upon the optimisation of anti-cancer therapeutic mAb through the manipulation of mAb structure. Ann received a PhD in Molecular and Cellular Biology from the MRC Clinical Research Centre, Harrow in 1991 then worked for 10 years in the United States on lipoprotein metabolism. After a career break with her young children Ann joined Professor Martin Glennie’s group in 2005 and is part of a programme for the discovery and optimisation of novel anti-cancer therapeutic mAb.
Agenda (Talk times include 5 – 10 minutes for questions)
Day 1: Advances in Cancer Screening and Prevention Research
09:30 – 10:10 Exhibitions open Registration and Refreshments
10:10 – 10:15 Introduction by the Chair Dr Eleanor O'Sullivan, Clinical Lecturer, Cork University Dental School & Hospital, Ireland
10:15 – 10:45 Estonian experience in establishing a cancer screening registry: opportunities and challenges of the e-health era
Dr Piret Veerus, Senior researcher, National Institute for Health Development, Estonia
10:45 – 11:15 Head and Neck Cancer (HNC) Screening in National and High-risk Populations in Ireland
Dr Eleanor O'Sullivan, Clinical Lecturer, Cork University Dental School & Hospital, Ireland
11:15 – 11:40 Session Break
Speakers’ photo, Refreshments, Poster viewing, Sponsors exhibition
11:40 – 12:10 Quality Control in Cervical Cancer Screening
Dr Alenka Repše Fokter, MD, Ph.D, MIAC, cytopathologist, Dept. of Pathology and Cytology, Celje general Hospital, Slovenia
12:10 - 12:55
Oral Presentations 12:10 – 12:25 HPV VACCINES HAVE NOT BEEN DEMONSTRATED TO BE SAFE OR EFFECTIVE IN THE PREVENTION OF CERVICAL CANCER
RJ Wilyman, University of Wollongong, School of Humanities and Social Inquiry, Australia
12:25 – 12:40 EFFECTIVENESS OF QUALITY CONTROLLED NATIONAL MAMMOGRAPHY SCREENING - THE ISRAELI EXPERIENCE AS A CASE STUDY
M. Ziv, Director General, Israel Cancer Association, Dr. Lital Keinan Boker, Israel Center for Disease Control, Israel Ministry of Health; University of Haifa. E. Robinson, Chairman of the Israel Cancer Association, Past-President of the Union for International Cancer Control (UICC).
12:40 – 12:55 THE ACCEPTANCE AND STIGMATISM OF HUMAN PAPILLOMAVIRUS VACCINATION (HPV) AMONG ADOLESCENT GIRL AND MOTHER DYADS IN HONG KONG
AY Loke; Kya Wong; A Chan School of Nursing, The Hong Kong Polytechnic University, Hong Kong
12:55 – 13:45 Session Break Lunch, Poster viewing, Sponsors exhibition
13:45– 14:30 Oral Presentations 13:45- 14:00 DEFINING THOSE AT HIGH RISK AND IN NEED OF PATIENT NAVIGATION TO LUNG CANCER SURGERY
Norma Kanarek , Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., Room E7541, Baltimore MD 21205
14:00 - 14:15 USING CANCER REGISTRY DATA TO EVALUATE ISRAELI NATIONAL SCREENING PROGRAMS FOR BREAST AND COLORECTAL CANCER
L Keinan-Boker, Israel Center for Disease Control, Israel Ministry of Health, Gertner Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel
14:15 – 14:30 THE IMPACT OF INTERVAL CANCERS IN COLORECTAL CANCER SCREENING USING FAECAL OCCULT BLOOD TESTING ON ADJUSTMENT TO A CANCER DIAGNOSIS AND ATTITUDES TOWARDS SCREENING
A Miles, Dr Anne Miles, Department of Psychological Sciences, Birkbeck, University of London, Malet Street, London WC1E 7HX.
14:30 – 14:50 Session Break Refreshments, Last poster viewing, Last exhibition
15:50 – 15:05 Oral Presentation COMPARISON OF UPTAKE OF COLORECTAL CANCER SCREENING BASED ON FAECAL IMMUNOCHEMICAL TESTING (FIT) IN MALES AND FEMALES: A SYSTEMATIC REVIEW AND META-ANALYSIS
N. Clarke, A. Osbourne, P. M. Kearney, L. Sharp National Cancer Registry, Building 3800, Cork Airport Business Park, Kinsale Road, Ireland
15:05 – 15:35 Towards implementation of lung cancer screening: refining methods to maximise effectiveness
Professor David Baldwin, Consultant Physician, Nottingham University Hospitals, UK
15:35 – 16:05 The European Prostate cancer screening trial ERSPC: outcomes and methods for risk stratification.
Dr Monique Roobol, Associate professor, epidemiologist, Erasmus University Medical center, Rotterdam, The Netherlands
16:05 – 16:35 Mammography Screening for Breast Cancer. Is it living up to its promise?
Dr Anthony Miller, Professor Emeritus, Dalla Lana School of Public Health, University of Toronto, Canada
16:35 – 17:05 A New Era in the Control of Breast Cancer Dr László Tabár, Professor emeritus, Department of Mammography, Falun Central Hospital, Falun, Sweden
17:05 Chairman’s Summing Up Close of Session
Day 2: Cancer Biomarker Discovery and Assay Development
09:30 – 10:10 Exhibitions open Registration and Refreshments
10:10 – 10:25 Introduction by the Chair Dr Mukesh Verma, Chief, Methods and Technologies Branch, Epidemiology and Genetics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health. Rockville, MD, USA
10:25 – 10:55 Mesenchymal and rare colorectal carcinomas as a paradigm to identify new biomarkers/alterations of tumor aggressiveness. New pathways, and an unexpected role of chromatin remodeling complexes
Dr Massimo Pancione, PhD Department of Sciences and Technologies, University of Sannio, Italy
10:55 – 11:25 RNAscope® - providing a unique insight into the interplay between cancer cells and the tumor microenvironment
Mr Barry Lynch, Director UK, Ireland & Scandinavia, Advanced Cell Diagnostics, Inc
11:25 – 11:55 Epigenetic markers of progression and treatment response in breast cancer
Dr Thomas Fleischer, University of Oslo, Norway.
11:55 – 12:15 Session Break
Speakers’ photo, Refreshments, Poster viewing Sponsors exhibition
12:15 – 12:30 Oral Presentation UNDERSTANDING FANCONI ANEMIA-ASSOCIATED INFLAMMATION THROUGH THE HIV AUXILIARY PROTEIN VPR N. Laguette, C. Brégnard and M. Benkirane. Institute of Human Genetics, CNRS UPR1142 141 Rue de la Cardonille, 34396 Montpellier cedex 5. France.
12:30 – 13:00 Nucleosomics® - A novel epigenetic biomarker discovery platform
Dr Mark Eccleston, Collaborations Manager, VolitionRx, Belgium
13:00 – 13:30 Novel biomarkers for hepatic fibrosis may help reduce progression to liver cancer
Dr Bevin Gangadharan, Oxford Antiviral Drug Discovery Unit, Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford, UK
13:30 – 14:15 Session Break Lunch, Poster viewing, Sponsors exhibition
14:15 – 14:35 Discussion session
14:35 – 15:05 Association of p53 and eIF4E with local recurrence in head and neck squamous cell carcinoma: Should we change the way used to assess the tumour margins?
Dr Rama Jayaraj, Charles Darwin University, Australia
15:05 – 15:35 Epigenetic biomarkers in cancer risk assessment, screening, and prevention
Dr Mukesh Verma, Chief, Methods and Technologies Branch, Epidemiology and Genetics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health. Rockville, MD, USA
15:35 – 16:00 Session Break
Refreshments, Last poster viewing, Last Sponsors exhibition
16:00 – 16:30 Mass spectrometry based discovery and quantitation of liver disease biomarkers before progression to cancer
Dr Abhinav Kumar, Oxford Antiviral Drug Discovery Unit, Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford, UK
16:30 – 17:00 Paediatric lymphoma: diagnosis, biomonitoring and therapy
Dr Suzanne Turner, Leukaemia and Lymphoma Research Lecturer, Department of Pathology, University of Cambridge, UK
17:00 Chairman’s Summing Up Close of Session
Day 3: Anti-Cancer Therapeutics: From research to trials to treatment
09:30 – 10:15 Exhibitions open Registration and Refreshments
10:15 – 10:30 Introduction by the Chair Dr Ann White, Senior Research Fellow, University of Southampton, UK
10:30 – 11:00 The selective targeting of cell survival pathways in cancer cells
Dr. Mark Guthridge, Senior Research Fellow, Australian Centre for Blood Diseases, Monash University, Melbourne, Australia
11:00 – 11:30 Early Oncology Drug Development - Current Strategies and Future Challenges.
Dr Hendrik-Tobias Arkenau, Medical Oncologist, Sarah Cannon Research Institute UK/University College London, UK
11:30 – 12:00 Session Break
Speakers’ photo, Refreshments, Poster viewing, Sponsors exhibition
12:00 – 12:30 Translating antibodies engineered with IgE Fc regions to elicit enhanced effector functions for cancer therapy
Dr. Sophia N. Karagiannis, Senior Research Fellow in Translational Cancer Immunology, Head of Cancer Antibody Discovery and Immunotherapy, St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, King's College London School of Medicine, UK
12:00 – 13:00 Oral Presentations 12:30 – 12:45 HMG-COA REDUCTASE REGULATES CCL17-INDUCED COLON CANCER CELL MIGRATION VIA GERANYLGERANYLATION AND RHOA ACTIVATION
A. Al-Haidari , Department of Clinical Sciences, Section of Surgery, Skåne University Hospital, Malmö, Lund, Sweden,
12:45 – 13:00 IN VIVO DRUG COMBINATION EFFECTS OF 1’S-1’-ACETOXYCHAVICOL ACETATE (ACA) AND 1’S-1’-ACETOXYCHAVICOL ACETATE (AEA) FROM ALPINIA CONCHIGERA ON HUMAN BREAST AND ORAL CANCER XENOGRAFTS
Noor Hasima Nagoor, Institute of Biological Science (Division of Genetics & Molecular Biology), Faculty of Science, University Malaya, 50603, Kuala Lumpur, Malaysia
13:00 – 14:00 Session Break Lunch, Poster viewing, Sponsors exhibition
14:00 – 14:30 Discussion session
14:30 – 15:00 Oral Presentations 14:30 – 14:45 INVESTIGATING THE EFFICACY OF COMBINING THYMOQUINONE WITH CLINICAL DRUGS TO ENHANCE CELL DEATH IN ADULT T-CELL LEUKEMIA
Hala-Gali Muhtasib. Department of Biology, American University of Beirut, Lebanon
14:45 – 15:00 THE PROMISE OF SONODYNAMIC THERAPY: USING ULTRASONIC IRRADIATION AND CHEMOTHERAPEUTIC AGENTS AS A TREATMENT MODALITY
Matthew Trendowski, Department of Biology-Syracuse University, Syracuse, NY, USA
15:00 – 15:30 Reporter Bioassay: A Novel, Bioluminescent Cell-Based Assay for Quantifying Fc Effector Function of Therapeutic Antibodies
Dr Craig Malcolm, Product Manager, Promega UK Ltd, Delta House, Southampton Science Park, Southampton, UK
15:30 – 15:50 Session Break Refreshments, Last poster viewing, Last Sponsors exhibition
15:50 – 16:00
Oral Presentation Patient Delay in accessing Breast Cancer Care in a LIC Moses Galukande, Makerere University, College of Health Sciences, Mulago hill, Kampala, Uganda
16:00 - 16:30 FKBPL and peptide derivatives and their dual anti-angiogenic and anti-cancer stem cell activity
Professor Tracy Robson, Professor of Experimental Therapeutics, Queen's University Belfast, Northern Ireland
16:30 – 17:00 Targeting leukemic stem cells to improve treatment of chronic myeloid leukemia.
Dr. Xiaoyan Jiang, Senior Scientist and Associate Professor, Terry Fox Laboratory, BC Cancer Agency Medical Genetics, University of British Columbia, Canada
17:00 Chairman’s Summing Up Close of Meeting
About the Speakers
Day 1
Piret Veerus has been involved in cancer screening research since 2004. Member of the European Network for Indicators on Cancer (EUNICE) 2005-2007; member of Eurochip-2 Task Force of Cervical Screening 2003-2007; member of Eurochip-3 WP4 on Cervical Cancer Screening 2008-2012. Member of expert panel of cancer screening in Estonia. Member of expert panel of cervical pathology diagnosis and surveillance guidelines in Estonia. Several international publications on cancer screening in Europe. Alenka Repše Fokter is Assistant Professor at Medical Faculty, University of Maribor, Slovenia and head of Cytopathology laboratory in Celje General Hospital. She is actively included in the national cervical cancer screening programme and is a member of the Slovenian advisory board of the national cervical cancer screening programme. She is a member of the Medical Chamber of Slovenia, Slovene Medical Association, Slovenian Society of Pathology, Slovenian Society of Cytopathology, European Society of Pathology, International Academy of Cytology, president of Expanded expert committee of Pathology and Forensic Medicine of the Ministry of Health and national editor of Acta Cytologica. David Baldwin works as a consultant respiratory physician, interventional bronchoscopist, and as lead clinician at the Nottingham Lung Cancer and Mesothelioma Centre at Nottingham University Hospitals.. He is Honorary Professor in the School of Medicine at the University of Nottingham. His primary research interests are in CT screening and lung cancer epidemiology. He is lead respiratory physician on the UK CT lung cancer screening trial (UKLS). He has published over 100 papers, written several chapters in well-known respiratory and general medical textbooks and has co-edited two books. He co-supervises post-graduate students for higher degrees and is on several trial development groups. He has held the positions of Honorary Secretary of the British Thoracic Society, Clinical Lead on the NICE Lung Cancer Guideline Development Group and Chair of the Quality Standards Group on Lung Cancer. He works with Public Health England and the National Cancer Research Institute. He enjoys time with his family and is a keen windsurfer and advanced instructor. Monique J. Roobol is associate professor and the head of the screening office of the Department of Urology at Erasmus Medical Centre Rotterdam, The Netherlands. She has a master and PhD degree in epidemiology. In the past she worked as a research technician in molecular biology. She is responsible for the Dutch part of the European Randomized study of Screening for prostate cancer (www.erspc.org) and the worldwide prostate cancer active surveillance project PRIAS (www.prias-project.org). She has (co)-authored app 200 scientific papers and book chapters. Anthony Miller, a physician-epidemiologist, was a scientific staff member, UK Medical Research Council, 1962-71, Director, Epidemiology Unit, National Cancer Institute of Canada, 1971-86, Chair, Department of Preventive Medicine and Biostatistics, University of Toronto, 1992-6, special expert, Division of Cancer Prevention, US National Cancer Institute, 1997, Senior Epidemiologist, International Agency for Research on Cancer, 1998-9, Head, Division of Cancer Epidemiology, German Cancer Research Centre, Heidelberg, 2000-3 and Associate Director, Research, Dalla Lana School of Public Health, University of Toronto, 2008-10. He is Scientific Lead of the Cancer Risk Management Initiative of the Canadian Partnership against Cancer. László Tabár is Professor emeritus of Radiology at the University of Uppsala School of Medicine, Sweden; founder and Director of the Medical Director of the Department of Mammography for 33 years at Falun Central Hospital, Sweden. He is the Project Leader of the Randomized Controlled Breast Cancer Screening Project in Kopparberg County, Sweden, where he has read over 1,000,000 mammographic screening examinations to date since 1977.Dr. Tabár is President of Mammography Education, Inc., Cave Creek, Arizona, Course director and principal lecturer of CME courses in breast imaging since 1980.
Day 2
Massimo Pancione: Born in 1974 in Benevento, Italy, received his BSc degree in Biological Sciences from Sannio University in Benevento. He completed his internship of 1 year at Department of Biochemical sciences, Federico II University, Naples, Italy. He worked for 2 years at Department of Pathology of the Fatebenefratelli Hospital in Benevento and Institute of food science CNR in Avellino, Italy. He spent a period as a visiting scientist at the CNIO, Madrid, Spain. He received his PhD in Molecular Biology from Sannio University in Benevento by working on the molecular mechanisms underlying colorectal cancer pathogenesis − with an emphasis on oncogenes and the function of tumour-suppressor genes. Since 2010 has been researcher of Molecular Biology at the University of Sannio. Thomas Fleischer, University of Oslo, Norway Obtained MSc in biology at the Norwegian University of Science and Technology in 2009. He did his PhD in Vessela N. Kristensens group at the Department of Genetics at the Norwegian Radium Hospital funded by the University in Oslo. He will defend his degree in June 2014. Mark Eccleston is a biotechnology entrepreneur and has held various roles includind CEO of Vivamer, a spin out from the University of Cambridge focussed on drug delivery, Director of Programmes at Aim listed ValiRx plc. where he managed preclinical development of an epigenetic therapeutics platform. He currently manages collaborations at VolitionRx. These activities are carried out through. Mark obtained a degree in chemistry and PhD Polymer Chemistry for Biomedical Applications from the University of Aston in Birmingham, UK. He later obtained an MBA (Entrepreneurship) from Dundee University through the Royal Society of Edinburghs Enterprise Fellowship Scheme. Bevin Gangadharan, obtained his DPhil under the supervision of Prof. Nicole Zitzmann at the University of Oxford where he carried out the first ever gel-based proteomics study to discover novel biomarkers for liver fibrosis. He has more than a decade of experience in proteomics and biomarker discovery and first started in this field in 2000 at Smithkline Beecham looking at depletion of albumin in plasma, an important approach in biomarker discovery. He has published in several peer-reviewed journals and has two patents on novel biomarkers for liver fibrosis. He is on the editorial board for Biomarker Research and gives proteomics lectures to students in the Department of Biochemistry at the University of Oxford.
Rama Jayaraj, is a cancer immunologist and is involved in molecular cancer marker study with Royal Darwin Hospital cancer surgeons and oncologists at Alan Walker Cancer Care Centre, Darwin, Australia. There are approximately 70 new cases of head and neck cancer/year at Royal Darwin Hospital and 45% of cancer patients are Australian Aboriginal and Torres Strait Islanders or Indigenous (despite being only 32% of the populace), and 90% of these patients present with ‘Stage III’ or ‘Stage IV’ tumours (very advanced stage tumours). There have been no meaningful studies done on the subset of Indigenous cancer patients in Northern Australia and his clinical research team including three research students (Methinee Intrapanya, Jagtar Singh and Dr Sheela Joseph) are currently working on molecular and immunodiagnostic cancer markers (P53, 4E and P16).
Abhinav Kumar, Oxford Antiviral Drug Discovery Unit, Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford, UK Abhinav Kumar holds a B.Sc. in Pharmacy, M.Sc. in Analytical Chemistry (University of Strathclyde, Glasgow, UK) and a Ph.D. in Bioanalytical Science (UWE, Bristol, UK). He received an award for the best poster by the European Society for Separation Science (EuSSC) for his HILIC application on polar biomarkers analysis and its biomedical applications (ISC 2012, Sept 2012, Torun, Poland). He has worked on untargeted metabolomics and many SRM method developments for the absolute quantification of compounds in biological samples. Presently he is working on proteomics research at the Department of Biochemistry, University of Oxford and is involved in LC-MS based protein biomarker discovery and SRM/PRM method development for absolute quantification. Suzanne Turner is a lecturer at the University of Cambridge where she heads a research group investigating mechanisms of lymphomagenesis with a special emphasis on paediatric cancers. Prior to taking this position, Suzanne was the recipient of the prestigious Leukaemia and Lymphoma Research Bennett Fellowship from 2007-2012. Suzanne received her training in oncology research at the Paterson Institute for Cancer Research in Manchester and this was followed by a postdoctoral training period with Dr Denis Alexander at the Babraham Institute in Cambridge, UK.
Day 3
Mark Guthridge is an NH&MRC Senior Research Fellow and heads the Leukemia Research Laboratory at the Australian Centre for Blood Diseases (ACBD), Monash University, Melbourne, Australia. Since 2000, his lab has received continual funding from International (NIH, AICR), National (NH&MRC, LFA) and State agencies (Cancer Council of SA) and his work has been published in leading journals including Cell, Molecular Cell, Cell Stem Cell, PLOS Biol and EMBO J. Dr. Guthridge regularly serves on the editorial boards of international peer-reviewed journals, national grant review panels and scientific organizing committees for international cancer conferences.
Hendrik-Tobias Arkenau, MD, PhD; Director, Drug Development, has vast experience in Early Oncology Clinical Drug Development with a special interest in gastrointestinal cancer and melanoma. He received his medical degree in 2000 at the Medical School Hanover, Germany, and completed his internship and specialist training in oncology in 2007. Before joining Sarah Cannon Research UK, he was senior clinical fellow at the Royal Marsden Hospital and team leader for Early Drug Development at the Prince of Wales Clinical School at the University of New South Wales, Sydney, Australia.
Sophia N. Karagiannis is a translational cancer immunologist specialising in antibody therapies for melanoma, ovarian and breast carcinomas. She received BA and MS degrees at Rutgers University, USA, having received scholarship awards and a teaching assistantship (1987, 1991), and a PhD at King’s College London in Biochemistry under SERC and SmithKline Beecham-funded scholarships (1995). She subsequently developed immunotherapeutic strategies for cancer and inflammatory diseases in academic and biotechnology environments in London and Cambridge as a postdoctoral associate and scientific investigator. She was appointed as NIHR Senior Research Fellow in 2007 and presently leads her own research group as Head of Cancer Antibody Discovery and Immunotherapy at King’s College London, focused on dissecting humoral immunity in cancer and leading research into tumour-targeting mechanisms of IgE antibodies and Th2 responses in cancer. Sophia co-founded the International Task Force on AllergoOncology and has pioneered IgE therapeutics for solid tumours. Her research and development initiative on the first IgE class antibody for cancer therapy is conducted in close collaboration with clinical and academic groups at King's College London and the CR-UK Drug Development Office. Tracy Robson is Professor of Experimental Therapeutics, School of Pharmacy, Queen’s University Belfast. She obtained her PhD from Imperial College, London. Her first academic post was as Lecturer in Radiation Science at the University of Ulster in 1997 and she then moved to the School of Pharmacy, Queen’s University of Belfast in 2004 to take up the post of Reader in Molecular Pharmacology. She was promoted to Professor in Oct 2010. Her main research focus is the development of novel approaches for sensitizing tumours to both radio and chemotherapy. She has published widely and holds several patents on both therapeutic and diagnostic approaches in the cancer area.
Xiaoyan Jiang is a Senior Scientist in the Terry Fox Laboratory of the BC Cancer Agency and a Professor in the Department of Medical Genetics at the University of British Columbia in Vancouver, Canada. She is an expert in basic and translational research of molecular properties of leukemic stem cells that contribute to the development of leukemia and drug resistance and has pioneered efforts to the development of new therapeutic approaches to directly target these critical cells. She has been invited to present at many international conferences and has organized and/or chaired a number of conference sessions. She has published numerous peers-reviewed publications, has been on the Editorial Board of 18 reputed journals and is the Editor-in-Chief of the World Journal of Hematology.
Discussion Sessions The discussion sessions are an opportunity for informal questions and answers. This is an ideal opportunity to get advice and opinion from experts in this area. This session is not for questions about specific talks, which can be asked after the speakers session, but for discussing either general topics or specific issues. There are three ways you can ask questions: 1. Before the session you can submit your question to Euroscicon staff at the registration desk, 2. Before and during the session you can submit a question or comments, by email, which will be provided on the day of the event 3. During the session you can put your hand up and join in
Session breaks All breaks and registrations will take place in the exhibition area where there will be lunch and refreshments. Please try to visit all the exhibition stands during this event. Not only do our sponsors enable Euroscicon to keep the registration fees competitive, but they are also here specifically to talk to you
Lunch
All the chicken in our lunch buffet is Halal
We have a number of dishes that are gluten free
We have a range of vegetarian dishes which are separated from the meat and fish dishes
Frequently asked questions about our events
Is the delegate list available? Yes this is available to everyone who attends the event and our sponsors. It is available in real time. To access the list please just log into your registration details or use the QR code on right of the agenda card which is provided on the day of the event. You will not be included in this list if you have opted out and you can do this by logging into your registration details. This list will not be sold or ever give out to third parties.
Can I have the speakers slides? We cannot give out the slides from our speaker’s presentations as they are deleted immediately after each event. If you require a particular set of slides please approach the speaker. We will however have a meeting report and you will be emailed when this report is published.
Can I have a notepad?
Notepads and pens are provided in the delegate bags and at the registration desk
How can I keep up to date with Euroscicon Events? To keep updated on our events and other Life Science News, please sign up for our newsletter at www.eurosciconnews.com
I don’t want my photograph on any Euroscicon promotional
material Please let our tech person know
Is there WIFI? Yes, please ask registration for log in details
Can I have a CPD certificate? CPD certificates will be available in the exhibition hall after lunch Please remember that EuroSciCon is a small independent company with no subsidies from society memberships or academic rates for venues. We try to be as reasonably priced as possible and our delegate rates are substantially lower than comparable commercial meeting organisations.
Euroscicon Ltd UK, Company Number: 4326921, Trading Address: Euroscicon Ltd, Highstone House, 165 High Street, Barnet, Herts. EN5 5SU, UK